Marija Krizic - University Hospital Centre Zagreb

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 18 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Real-world comparison of the efficacy of three CDK4/6 inhibitors (CDK4/6i) in the first-line treatment of endocrine-sensitive advanced breast cancer (aBC): Single institution experience

Natalija Dedic Plavetic,Katarina Čular,Dora Gudelj, Kristina Kaceljak,Marija Križić,Marina Popovic, Stela Bulimbašić,Maja Sirotković-Skerlev, Sanda Bubanović,Tajana Silovski

Journal of Clinical Oncologyno. 16_suppl (2024)

引用0浏览0引用

Real-world Outcomes of Dual HER2 Blockade Therapy in Metastatic HER2-Positive Breast Cancer: from Induction to Maintenance

Marija Križić,Marina Popović,Tajana Silovski,Dorotea Grbin,Natalija Dedić Plavetić

Drugs - Real World Outcomes (2024)

引用0浏览0WOS引用

Abstract PO3-05-04: Characteristics and Clinical Outcome of Patients with HR Positive HER2 Low Metastatic Breast Cancer Treated with CDK 4/6 Inhibitors

Katarina Čular, Kristina Kanceljak, Ana Magdalena Glas,Dora Gudelj,Marija Križić,Marina Popović,Natalija Dedić Plavetić,Maja Sirotković-Skerlev,Stjepko Pleština,Tajana Silovski

Cancer Researchno. 9_Supplement (2024): PO3-05

引用0浏览0引用

Abstract PO4-02-09: Clinical Outcomes of Neoadjuvant Chemotherapy in HER2-low Early Breast Cancer

Dora Gudelj,Katarina Čular, Lea Toula,Marija Križić,Marina Popović,Natalija Dedić Plavetić, Ana Kelečić, Gordana Ivanac,Majana Soče, Iva Kukal Gjergjaj,Tajana Silovski

Cancer Researchno. 9_Supplement (2024): PO4-02

引用0浏览0引用

Real-world Comparison of the Efficacy of Three CDK4/6 Inhibitors (cdk4/6i) in the First-Line Treatment of Endocrine-Sensitive Advanced Breast Cancer (abc): Single Institution Experience

Natalija Dedic Plavetic,Katarina Cular,Dora Gudelj, Kristina Kaceljak,Marija Krizic,Marina Popovic,Stela Bulimbasic,Maja Sirotkovic-Skerlev, Sanda Bubanovic,Tajana Silovski

JOURNAL OF CLINICAL ONCOLOGYno. 16 (2024)

引用0浏览0引用

Je Li Trudnoća Sigurna Kod Bolesnica S Rakom Dojke Koje Su Nositeljice BRCA 1/2 Mutacije

Tajana Silovski,Marina Popović,Marija Križić, Natalija Dedić-Plavetić

Bolesti dojkepp.73-83, (2024)

引用0浏览0引用

HER2 Low Breast Cancer: A New Subtype or a Trojan for Cytotoxic Drug Delivery

Marina Popović,Tajana Silovski,Marija Križić,Natalija Dedić Plavetić

International journal of molecular sciences（2023）

引用5浏览0WOS引用

Abstract P4-01-39: Real-world Efficaccy of Dual Antiher2 Therapy in First Line Metastatic HER2-positive Breast Cancer and the Possibility of Prediction of Long-Term Response

Marija Križić,Tajana Silovski,Marina Popović,Natalija Dedić Plavetić

Cancer researchno. 5_Supplement (2023): P4-39

引用0浏览0引用

Liječenje Vođeno Sveobuhvatnim Genskim Profiliranjem U Bolesnica S Proširenim Rakom Dojke

Tajana Silovski,Natalija Dedić Plavetić,Marina Popović,Marija Križić,Katarina Čular,Dora Gudelj,Marko Lovrić, Kristina Kanceljak

Bolesti dojkepp.61-71, (2023)

引用0浏览0引用

Clinical Characteristics and Outcome of PIK3CA Mutated Hormone Receptor Positive (HR+), Human Epidermal Growth Factor 2 Negative (HER2-), Advanced Breast Cancer (BC) Treated with Cyclin-Dependent Kinase 4/6 Inhibitors (cdk4/6i): Real World Data

Natalija Dedic Plavetic,Katarina Cular,Marija Krizic,Marina Popovic,Stjepko Plestina,Tajana Silovski

JOURNAL OF CLINICAL ONCOLOGYno. 16 (2023)

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn